INTRODUCTION
We have implemented a software package, GeneRecon, based on extensions of the shattered coalescence model of Morris et al. (2002) for Bayesian Markov chain Monte Carlo (MCMC) finescale linkage disequilibrium (LD) gene mapping. GeneRecon uses the coalescent model (Hein et al., 2005) to explicitly model the genealogy of a sample of case chromosomes. The location of the mutation influencing the disease is inferred based on the observed LD at multiple genetic markers. Given the computational complexity of the problem, a Metropolis-Hastings algorithm is deployed to integrate over unknown population genetic parameters of the coalescence model and sample the marginal posterior probability density for the parameter(s) of interest.
THE MODEL
GeneRecon handles both SNP and microsatellite marker genotype or haplotype data from case/control design studies. Phenocopies and locus-and allele-heterogeneity are modeled in two ways. First, the 'shattered' coalescent allows genealogical independence of coalescent subtrees (Morris et al., 2002) . Second, cases are partitioned into two clusters, a 'null'-cluster which is not evaluated by the model, and hence greatly reduces the search space, and a 'mutation'-cluster of cases which is evaluated by the model .
IMPLEMENTATION
GeneRecon can be obtained from its homepage, where instructions for the installation are provided. The MCMC engine of GeneRecon is written in C++ and is available as a command-line executable for Linux. A 'Getting started' document provides an introduction to the functionality of GeneRecon, whereas a user's manual provides examples of more advanced uses, including examples of using Guile Scheme.
FLEXIBILITY OF USING SCHEME
Using the Guile Scheme programming language as a front-end for input specifications and execution control allows a highly flexible interaction with the MCMC engine of GeneRecon. A collection of Guile modules allow easy changes to functionality specifications. Input file format, population genetic parameters, MCMC sampling strategy and output options can be configured. Prior knowledge of population genetic parameters, such as effective population size (N e ) or local recombination rates (r) may be explicitly defined, if available from independent sources such as HapMap or the DeCODE genetic map. At Present, sampling of the likelihood, disease location, effective population size, coalescent tree and cluster indices are supported. The MCMC sampling strategy is defined by the number of iterations, the burn-in period and the proposal densities of the sampled parameters. The choice of strategy will strongly affect the mixing properties of the Markov chain and convergence to a stationary distibution [for details on MCMC stategies see Gilks et al. (1995) or ].
PERFORMANCE
To evaluate the prediction capabilities of GeneRecon, we have conducted a large simulation study (Mailund et al., 2005a) , where sequence data were simulated under various parameters using the CoaSim tool (Mailund et al., 2005b) , and then analyzed using GeneRecon, with four independent runs for each dataset. Results for a Mendelian scenario, i.e. all cases carry the disease causing mutation and all controls are wild types, are shown in Table 1 .
We have also tested GeneRecon on the DF508 mutation for cystic fibrosis data from Kerem et al. (1989) . The results from this analysis Ã To whom correspondence should be addressed. are shown in Figure 1 . GeneRecon compares favorably with other fine-maping tools (Table 2) .
CONCLUSION
GeneRecon is designed to allow flexible multimarker LD mapping using coalescent model. Adaptations and extensions of the various Scheme modules provided allow users to accomodate a wide range of scenarios, data types, sampling strategies and convergence diagnostics, without much loss of user friendliness compared to competing software. The table shows the number of chains inferring a disease locus in the given distance from the true locus at the 50, 75 and 95% quantile, respectively. Six setups were explored in two GeneRecon settings. In setting one, all cases were considered by the coalescence model, whereas in setting two the fraction of cases evaluated by the model was 50%. In the first setup a region of 1 cM is covered by 20 markers of minor allele frequency (MAF) >10% and a trait locus with disease allele frequency of 20%, all placed at random, in the second setup the density of markers is doubled and in the third setup region is twice the size. Setup four to six follow this pattern, but in a smaller region (0.1 for setup four and five and 0.2 cM for setup six). That the accuracy is decreased when the number of markers are doubled, as seen in setup two and five, may seem counter-intuitive, but is a consequence of the increase in the search space. GeneRecon explored the search spaces of all setups for four CPU days each, regardless of the number of markers, so doubling of this number leads to the evaluation of a smaller fraction of the search space, causing the reduction in accuracy. Fig. 1 . Example of GeneRecon inferring the position of the DF508 mutation for cystic fibrosis with data from Kerem et al. (1989) . The MCMC was allowed to burn in for 20-000 iterations and the posterior was sampled from the following 180-000 iteration. In the posterior plot, the true position is indicated by the solid vertical line and the 95% credibility interval is indicated by dashed vertical lines. Ticks at the x-axis indicate the position of SNP markers. The mutation is located at 0.88.
